These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34953482)

  • 21. A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.
    Bagel J; Zapata J; Nelson E
    J Drugs Dermatol; 2018 Aug; 17(8):845-850. PubMed ID: 30124723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological therapy for pustular psoriasis: a systematic review.
    Falto-Aizpurua LA; Martin-Garcia RF; Carrasquillo OY; Nevares-Pomales OW; Sánchez-Flores X; Lorenzo-Rios D
    Int J Dermatol; 2020 Mar; 59(3):284-296. PubMed ID: 31612467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis results do not reflect the real safety of biologics in psoriasis.
    Afach S; Chaimani A; Evrenoglou T; Penso L; Brouste E; Sbidian E; Le Cleach L
    Br J Dermatol; 2021 Mar; 184(3):415-424. PubMed ID: 32446286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous adverse effects of biologic drugs in psoriasis: a literature review.
    Šuler Baglama Š; Trčko K
    Acta Dermatovenerol Alp Pannonica Adriat; 2021 Dec; 30(4):149-156. PubMed ID: 34929991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tildrakizumab for Moderate-to-Severe Plaque Psoriasis.
    Mui UN; Patel RR; Vangipuram R; Tyring SK
    Skin Therapy Lett; 2019 Nov; 24(6):1-4. PubMed ID: 31801012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Guselkumab for the Treatment of Psoriasis.
    Machado Á; Torres T
    BioDrugs; 2018 Apr; 32(2):119-128. PubMed ID: 29470778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment.
    Guttman-Yassky E; Krueger JG; Lebwohl MG
    Exp Dermatol; 2018 Apr; 27(4):409-417. PubMed ID: 28266782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review.
    Maliyar K; Crowley EL; Rodriguez-Bolanos F; O'Toole A; Gooderham MJ
    J Cutan Med Surg; 2019; 23(4):428-435. PubMed ID: 30938189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
    Ryan C; Leonardi CL; Krueger JG; Kimball AB; Strober BE; Gordon KB; Langley RG; de Lemos JA; Daoud Y; Blankenship D; Kazi S; Kaplan DH; Friedewald VE; Menter A
    JAMA; 2011 Aug; 306(8):864-71. PubMed ID: 21862748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis.
    No DJ; Amin M; Bhutani T; Wu JJ
    J Dermatolog Treat; 2018 Aug; 29(5):467-474. PubMed ID: 29103334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis.
    Erichsen CY; Jensen P; Kofoed K
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):30-38. PubMed ID: 31419343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.
    Al-Janabi A; Foulkes AC; Mason K; Smith CH; Griffiths CEM; Warren RB
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1440-1448. PubMed ID: 31997406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management.
    Carrascosa JM; Del-Alcazar E
    Expert Rev Clin Immunol; 2018 Apr; 14(4):259-273. PubMed ID: 29557200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Systemic Medications Among Older Adults With Psoriasis and Atopic Dermatitis: A Systematic Review of Observational Studies.
    Tang E; Maqbool T; Lam M; Adam GP; Tadrous M; Rochon PA; Drucker AM
    J Cutan Med Surg; 2021; 25(4):397-408. PubMed ID: 33566683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Infectious risk].
    Calabuig E; Salavert M
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis.
    Zhou Q; Zhou S; Xiong H; Yang J; Yang Z; Zhou N; Mao J; Li M
    Clin Cosmet Investig Dermatol; 2023; 16():1493-1497. PubMed ID: 37333515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.
    Johnston A; Guzman AM; Swindell WR; Wang F; Kang S; Gudjonsson JE
    Br J Dermatol; 2014 Jul; 171(1):97-107. PubMed ID: 24601997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.